[Endovascular therapy for peripheral arterial disease].

Interventionelle Therapie der peripheren arteriellen Verschlusskrankheit.

Journal

Deutsche medizinische Wochenschrift (1946)
ISSN: 1439-4413
Titre abrégé: Dtsch Med Wochenschr
Pays: Germany
ID NLM: 0006723

Informations de publication

Date de publication:
10 2023
Historique:
medline: 23 10 2023
pubmed: 28 9 2023
entrez: 27 9 2023
Statut: ppublish

Résumé

In addition to conservative therapy with intensive walking training, endovascular revascularisation and open vascular surgical revascularisation are of high importance in the treatment of peripheral arterial disease. Over the past decades, endovascular therapy has developed considerably and is now the treatment of choice for most vascular segments. The use of different devices has been shown to be beneficial for different vessel segments. Primary stent angioplasty has been shown to be superior to balloon angioplasty with secondary stent implantation for the treatment of iliac lesions. Femoropopliteal, the use of paclitaxel-eluting balloon angioplasty is recommended. A mortality signal shown in a meta-analysis was not confirmed. With directional atherectomy and intravascular lithotripsy, different options for plaque modification are available. The cytostatic drug sirolimus as another antirestenotic substance still has to be investigated in large, randomised trials. A final assessment of the effectiveness and safety is not yet possible. Infrapopliteal balloon angioplasty remains the standard treatment. After interventional therapy, regular follow-up is recommended.

Identifiants

pubmed: 37757890
doi: 10.1055/a-2017-7786
doi:

Substances chimiques

Coated Materials, Biocompatible 0

Types de publication

English Abstract Journal Article

Langues

ger

Sous-ensembles de citation

IM

Pagination

1301-1306

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

Tanja Böhme: keine Interessenkonflikte. Thomas Zeller: Honorare von: Abbott Vascular, BIBA Medical, Biotronik, Boston Scientific Corp., Cook Medical, Efemoral, Gore & Associates, Medtronic, Philips-Spectranetics, Shockwave, Veryan. Consulted for: Boston Scientific Corp., CSI, Gore & Associates, Medtronic, Veryan, Philips-Intact Vascular, Shockwave, Bayer, Vesper Medical, VentureMed, ANT. Institutionelle Zuschüsse für Forschung, klinische Studien oder Arzneimittelstudien von: Bard Peripheral Vascular, Veryan, Biotronik, Cook Medical, Gore & Associates, Medtronic, Philips, Terumo, TriReme, Shockwave, Med Alliance, Intact Vascular, B. Braun; CSI, Boston Scientific, University of Jena, Pluristem, Philips, PQ Bypass, Surmodics, Alative Solutions, Reflow Medical

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH